The 'Responsible Communication of Machine Learning Research in Biomedicine' workshop will bridge the translation gap between machine learning researchers and the domain scientists, clinicians and policymakers who must interpret and act on their findings.
A persistent gap has emerged between what machine learning (ML) systems can deliver in biomedical contexts and how their capabilities are communicated to those who use or regulate them. In early discovery, high-profile systems such as AlphaFold and agentic research platforms such as AI Scientists have increasingly accelerated the pace at which unchecked capability claims enter public and policy discourse. In clinical deployment, decision-making tools are expanding rapidly but frameworks for communicating their limitations remain underdeveloped, illustrated by well-documented cases of oncology decision-support tools overstating their clinical capabilities, as well as more recent findings that LLMs achieving near-perfect medical benchmark scores fail to improve clinical decision-making with real patients. Across the pipeline, this gap drives hype, misuse, misinterpretation and poorly informed governance, with direct consequences for user trust, funding priorities and the effective adoption of advances in ML.
In early discovery, frameworks to address this challenge are largely absent; in clinical settings, reporting standards such as TRIPOD+AI and TRIPOD-LLM represent important steps but adherence remains low. A deeper contributing challenge is that the technical conventions and vocabulary that make findings legible within ML do not translate cleanly across the diverse stakeholders involved: researchers, clinicians, policymakers and those responsible for communicating advances more broadly frequently lack a common language and are left uncertain about what ML systems can and cannot do and unable to evaluate their claims. Because the challenges arise in the translation between communities, reporting standards alone or solutions developed by a single community in isolation cannot feasibly close the gap that unintended miscommunication creates.
In response, this workshop treats structured interdisciplinary dialogue as the method. Initiated from within the ML research community, it brings those who produce ML findings into direct exchange with the domain scientists, clinicians, policymakers, journalists and science communicators who must interpret and act on them. Previous NeurIPS, ICML and ICLR workshops have advanced related themes primarily from the ML perspective, including explainability, interpretability and responsible AI. This workshop builds on that foundation by shifting focus from how findings are communicated within ML to how they translate across the biomedical landscape and those who shape it. Grounded in real-world case studies, the workshop is designed to surface opportunities for evidence-based communication approaches when moving from problem to practice, with interdisciplinary exchange at its core.
Important dates
Call for papers: Now open – submission via OpenReview
Submission deadline: 29 August 2026 (AOE)
Author notifications: 29 September 2026 (AOE)
Workshop date: 11 or 12 December 2026 (TBC)
Coming soon
Speaker lineup and agenda will be shared here in advance of the workshop.
Organizers

Siobhan Sanford
GSK AIML

Julia Meister
GSK AIML

Qiyao Wei
Cambridge University

Galvin Khara
GSK AIML

Nikhil Kurian
Adelaide University

Ben Glocker
Imperial University

Jessica Schrouff
GSK AIML
Questions?
Contact the organizers: translating.ml.research@gmail.com
This workshop is part of NeurIPS 2026. For general conference information, visit neurips.cc.